PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2010
CASE
AUTH/2318/5/10 Novo Nordisk

AUTH/2318/5/10: Specialist diabetes registrar v Novo Nordisk (Victoza) β€” US CME follow-up email (No breach)

Complaint about a US third-party CME follow-up email allegedly promoting Victoza and giving misleading renal impairment safety info. Panel found the email…

2018
CASE
AUTH/3013/1/18 AstraZeneca

AUTH/3013/1/18: AstraZeneca employee complaintβ€”uncertified global advisory board and incomplete/inaccurate information to PMCPA

Anonymous employee alleged poor global Code training and a questionable advisory board. Panel found breaches for failure to certify and high standards;…

2019
CASE
AUTH/3187/5/19 Cipla

AUTH/3187/5/19: Anonymous representative v Cipla β€” conduct of a senior manager (No breach)

Anonymous complaint alleged a Cipla senior manager pressured switching, linked education support to sales, discussed off-label spacer use, worked exhibition stands without…

2019
CASE
AUTH/3155/2/19 Bristol-Myers Squibb ⭐ Case of the Week

Bristol-Myers Squibb & Pfizer: Eliquis HCP website omitted SSRI/SNRI bleeding-risk caution (AUTH/3155/2/19, AUTH/3156/2/19)

Eliquis HCP website listed NSAID/aspirin caution but omitted similar SSRI/SNRI cautions added to the updated SmPC. Panel found the page misleading and…

2019
CASE
Diurnal

Diurnal: β€œProducts and Pipeline” webpage ruled promotionalβ€”pre-licence pipeline promotion and missing PI

Diurnal’s health professional webpage combined a licensed product with pipeline products and implied they were β€œeffective, high quality”. PMCPA ruled this promoted…

2010
CASE
AUTH/2357/9/10 Boehringer Ingelheim

AUTH/2357/9/10: Boehringer Ingelheim – Pradaxa ad claimed β€œequivalent” efficacy and safety vs enoxaparin based on non-inferiority studies

A GP challenged a Pradaxa journal ad claiming β€œefficacy and safety equivalent to enoxaparin”. PMCPA ruled the equivalence message (reinforced by balanced…

2011
CASE
AUTH/2379/1/11 Chiesi

Chiesi: Sponsored respiratory journal on BTS stand seen as promoting Fostair for unlicensed COPD use (AUTH/2379/1/11)

A Chiesi-sponsored journal handed out from a BTS promotional stand included COPD-focused content and a Fostair ad. The Panel ruled this effectively…

2011
CASE
AUTH/2399/4/11 Vifor Pharma

Vifor Pharma: third-party email about Ferinject found misleading (AUTH/2399/4/11)

A third-party email promoting a Ferinject video implied other IV irons required multiple hospital visits. PMCPA held Vifor responsible for the distributor…

2011
CASE
AUTH/2380/1/11 Allergan ⭐ Case of the Week

AUTH/2380/1/11: Merz Pharma v Allergan β€” β€œNo set dose ratio” claim on Botox exhibition panel (No breach)

Merz challenged Allergan’s National Stroke Forum panel claiming β€œNo set dose ratio has been established between BoNT-A formulations”. The PMCPA ruled the…

2018
CASE
AUTH/3090/9/18 Novartis Pharmaceuticals UK

AUTH/3090/9/18: Director v Novartis (clinical trial disclosure) – No breach

BMJ analysis suggested Novartis had β€œdue trials” without results on EUCTR. PMCPA found most trials were out of UK Code scope or…

2011
CASE
AUTH/2404/5/11 Boehringer Ingelheim

Boehringer Ingelheim: Consumer press release and spokesperson briefing promoted Pradaxa for unlicensed stroke prevention (AUTH/2404/5/11)

A GP complaint about UK newspaper coverage led to findings that a consumer press release and spokesperson briefing effectively promoted Pradaxa (dabigatran)…

2011
CASE
AUTH/2424/8/11 Boehringer Ingelheim

AUTH/2424/8/11 & AUTH/2425/8/11: Sponsored linagliptin article ruled disguised pre-licence promotion (Boehringer Ingelheim breach; Lilly no breach)

A GP challenged a sponsored Future Prescriber article on linagliptin as misleading pre-licence promotion. PMCPA held Boehringer Ingelheim responsible and found multiple…

2018
CASE
AUTH/3073/9/18 Novartis Pharmaceuticals UK

AUTH/3073/9/18: Director v Novartis β€” Clinical trial disclosure (outwith scope; no breach)

PMCPA case AUTH/3073/9/18 (Director v Novartis) concerned clinical trial disclosure. The matter was ruled outwith the scope of the ABPI Code (2016).…

2018
CASE
AUTH/3075/9/18 Lundbeck ⭐ Case of the Week

AUTH/3075/9/18: Director v Lundbeck β€” Clinical trial disclosure (outwith scope; no breach)

PMCPA case AUTH/3075/9/18 (Director v Lundbeck) concerned clinical trial disclosure but was ruled outwith the scope of the ABPI Code (2016). No…

2012
CASE
AUTH/2519/6/12 Eli Lilly

Lilly poster β€œHall of Fame” photo competition: sales manager incentive scheme led to Code breaches (AUTH/2519/6/12)

A GP complained a Lilly rep insisted on photos with a diabetes foot pain poster to win prizes. PMCPA found breaches for…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training